Former Interim Chief Executive Officer · Alaunos Therapeutics, Inc. (TCRT)

Heidi Hagen

FY2021 is the first fiscal year CompBrief holds for Heidi Hagen as a named executive officer of Alaunos Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,730,871

Salary $306,947Stock awards $387,900Bonus $200,000

2nd of 6 named executive officers at Alaunos Therapeutics by FY2021 total.

6 named officers on file for Alaunos Therapeutics, FY2021

Heidi Hagen’s pay file — $29

  • 1 fiscal year of pay, line by line
  • TCRT’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Alaunos Therapeutics’s whole pay program stands against its peers

  • Alaunos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2022 (DEF 14A).

Free

Get Heidi Hagen’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Heidi Hagen compensation by year

Alaunos Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Alaunos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$306,947
Bonus$200,000
Stock awards$387,900
Option awards$1,795,770
Non-equity incentive$0
Pension and deferred compensation$0
All other$40,254
Total$2,730,871

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. DEF 14A filed April 27, 2022, accession 0001193125-22-123703, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-22-123703. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2022.

Alaunos Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Kevin Boyle Sr.Chief Executive Officer$4,573,753
Heidi Hagen · this pageFormer Interim Chief Executive Officer$2,730,871
Eleanor de GrootEVP, Operations$2,174,017
Jill BuckFormer EVP, GM Gene Therapy$1,873,742
Laurence CooperFormer Chief Executive Officer$1,531,130
Raffaele BaffaChief Medical Officer$1,034,270

Board service

Alaunos Therapeutics board · FY2021
Director compensation in US dollars, as Alaunos Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2021$19,446$0$0—$19,446

Each year as the company reported it in Alaunos Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Alaunos Therapeutics pays directors a $50,000 cash retainer. As stated in Alaunos Therapeutics's FY2021 proxy.

The full Alaunos Therapeutics compensation record

free company brief

This page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Alaunos Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Heidi Hagen's compensation dossier · One-time report. No refunds.